Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Hugh presenting To some of Canada's top healthcare leaders
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Comment by jopatcloon Jun 24, 2024 9:39am
27 Views
Post# 36103034

RE:Hugh presenting To some of Canada's top healthcare leaders

RE:Hugh presenting To some of Canada's top healthcare leadersgood open TSX-V 0.22   and at any time news from the FDA V4.0 We are now preparing for product launch and market entry for what we believe is a product that promises true benefits for patients, clinicians and healthcare providers. In the post on Linkein Hugh MacNaught President and CEO at Ventripoint Diagnostics Ltd. 5 days ago During the past several months Ventripoint has released VMS+ V3.2 and submitted V4.0 to FDA for 510(k) clearance. We are now preparing for product launch and market entry for what we believe is a product that promises true benefits for patients, clinicians and healthcare providers.
good comment @nicolaosK It will be the standard of care for the uk. Nhs was waiting for funding and version 3.2

@cardinal Bart is a long way into sales in Europe. As they stated Q3 will be more consistent sales
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities